medical research

Side-effects reporting for drug trials + more

Submitted by Carlyn Zwarenstein on September 16, 2014 - 12:00

Over the years, Open Medicine authors have taken a strong interest in research ethics and particularly the dangers of overly-close or conflicted relationships with pharmaceutical and medical device companies. As you may have intuited from the "closed for submissions" notice on our home page, for a variety of reasons Open Medicine is going to be closing up shop over the next couple of months.

Funding systems and what gets funded

Submitted by Carlyn Zwarenstein on September 5, 2014 - 17:01

So, IS there a creativity deficit in science? If there is, what's causing it? This article by scientist Ben McNeil looks at publish-or-perish, the problem with preliminary data, risk-averse funding, the age bias and lots more. Definitely worth checking out.

Drug development in the sharing economy

Submitted by Carlyn Zwarenstein on June 23, 2014 - 13:55

Sharing—what a concept. With scientific research tending in two directions—on one hand, towards more proprietary knowledge and more expensive and limited access, and on the other, towards open data and open access publications—it is interesting to note a new private-public partnership based in Toronto and New York that will provide completely open access to anyone who wants to use its structural genomics data. Is this what real sharing of information should look like?